Quarterly report [Sections 13 or 15(d)]

Significant Accounting Policies and Estimates (Tables)

v3.26.1
Significant Accounting Policies and Estimates (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents
    June 30,     June 30,  
    2026     2025  
Cash   $ 492     $ 725  
Restricted cash     1,214       -  
Total cash and restricted cash shown in the statement of cash flows   $ 1,706     $ 725  
Schedule of Fair Value of Derivative Liabilities

    Level 1     Level 2     Level 3     Total  
Derivative liability as of June 30, 2026 ($ in thousands)   $     $     $ 8,665     $ 8,665  
Schedule of Level 3 Roll-forward for Derivative Liabilities

Level 3 Roll-forward

 

    Amount ($ in thousands)  
Balance at January 1, 2026   $  
Initial recognition of derivative liability     10,101  
Changes in fair value     (1,436 )
Balance at June 30, 2026   $ 8,665  

Schedule of Disaggregated Revenue by Sales Type

Disaggregated revenue by sales type ($ in thousands):

    2026     2025  
    Three Months Ended  
    June 30,  
    2026     2025  
Contract manufacturing   $ 1,038     $ 863  
Custom and white label finished goods manufacturing     -       27  
Consumer branded products     1,756       1,884  
Medical devices/other     78       110  
Biomaterial products     814       -  
Total   $ 3,686     $ 2,884  

 

    2026     2025  
    Six Months Ended  
    June 30,  
    2026     2025  
Contract manufacturing   $ 1,954     $ 1,811  
Custom and white label finished goods manufacturing     -       27  
Consumer branded products     3,377       3,666  
Medical devices/other     191       186  
Biomaterial products     814       -  
Total   $ 6,336     $ 5,690